

# SARS-CoV-2 (COVID-19) SEROLOGY TESTING AVAILABLE

**CLH Test Code:**  
COVIGG

**CPT Code:**  
86769

**Test Name:**  
SARS-CoV-2 IgG Antibody

**Specimen type:**  
Serum

**Estimated Turn-around time:**  
24 Hours

**Testing performed:**  
7 days a week

## Client Services

808.677.7998 ..... Oahu

866.281.6816 ..... Oahu (Toll free)

## To Schedule patient appointments

833.920.2559 ..... Oahu (Toll free)

**Visit our website at:**

[www.clinicallabs.com](http://www.clinicallabs.com)

Effective April 30, 2020, Clinical Laboratories of Hawaii (CLH) will begin offering serologic testing for antibodies to SARS-CoV-2, the virus that causes COVID-19. The test conducted on the Abbott Architect platform is a chemiluminescent microparticle assay (CMIA) that will detect IgG antibodies to SARS-CoV-2 with 99% specificity in serum specimens. These antibodies are specific proteins found in blood and are produced by a person's immune system as a result of infection. This test has received Emergency use Authorization (EUA) by the Food and Drug Administration (FDA).

**Serologic testing alone should NOT be used to diagnose ACTIVE infections by SARS-CoV-2, as antibodies are produced weeks after the initial viral exposure. The only acceptable method to diagnose an active infection is via molecular amplification of viral nucleic acid, such as real-time reverse-transcription polymerase chain reaction (rRT-PCR). CLH currently offers this molecular COVID-19 test for active infection detection.**

Serological testing has been proposed for a variety of applications such as:

- Determining which persons may have developed immunity to SARS-CoV-2 (this needs to be confirmed)
- Assessing the number of persons exposed to the virus for epidemiologic purposes
- Evaluating potential candidates for convalescent plasma donation

A positive IgG antibody result indicates exposure to SARS-CoV-2. The majority of patients with infection have IgG seroconversion after 14 days. A positive serology result does NOT mean the virus is inactive.

A negative serology result indicates that an individual has no detectable antibodies at the time of testing. This could be due to non-exposure to virus, testing too early in the course of viral infection, or the lack of an adequate immune response (i.e., immunosuppression).

Clinical evaluation and confirmation with SARS-CoV-2 molecular testing must be made to diagnose an active infection. We also recommend that providers follow the guidelines from the Centers for Disease Control and Prevention\* (CDC) and the Hawai'i Department of Health (HDOH).

Asymptomatic patients may be directed to Clinical Labs of Hawaii locations for specimen collection. For assistance with patients exhibiting fever/cough or who are immunocompromised, please contact our Client Services Department at (808) 677-7998 or call 1-833-920-2559 (toll free) to schedule an appointment at select locations. You may also visit our website at [www.clinicallabs.com](http://www.clinicallabs.com) for additional information.

Insurance coverage is based on determination of medical necessity. Healthcare providers and patients are advised to contact their insurance company directly for coverage eligibility.

\* <https://www.cdc.gov/coronavirus/2019-ncov/lab/serology-testing.html>

Thank you for choosing Clinical Labs of Hawaii.